| | Tumor-specific nuclear targeting: Promises for anti-cancer therapy?Received 13 January 2006; received in revised form 20 February 2006; accepted 20 February 2006. published online 17 April 2006. Abstract Recent developments in anti-cancer gene therapy suggest that the idea of a magic bullet for cancer may not be a pipe dream. Viral-based anti-cancer vectors for gene therapy have been used preferentially in this regard, but recent results from clinical trials have raised serious concerns as to their safety. For this reason, the development of non-viral vectors able to deliver drugs or suicide genes specifically to cancer cells is of paramount importance. In this context, great interest has been raised by recent reports that several proteins, including viral protein 3 (VP3 or Apoptin) from Chicken Anemia Virus, are capable of selectively killing tumor cells. Intriguingly, VP3's anti-cancer activity is strongly linked to its ability to localize more efficiently in the nucleus of cancer and transformed cells than that of normal, non-transformed cells with a tumor cell-specific nuclear targeting signal (tNTS) located at the C-terminus of the protein. Clearly, the VP3 tNTS is an exciting prospect to enhance non-viral-mediated cancer cell killing. This review will discuss recent advances in the understanding of the mechanism responsible for VP3 tumor-specific nuclear localization, including its specific phosphorylation, and the implications for the enhancement of anti-cancer therapy. It also proposes alternative strategies to develop tNTSs for anti-cancer therapies. Keywords: Nuclear targeting, Apoptin, Cancer, Nuclear targeting signal, Apoptosis, Vehicle, Modular transporters, Therapy, Gene therapy, Drug delivery, VP3, Anti-cancer, Photosensitizers 1. Introduction  Cancer can be regarded as a heterogeneous group of proliferative diseases, resulting from the accumulation of genetic lesions. Despite considerable advances in our understanding of the molecular mechanisms of carcinogenesis and cancer progression, cancer remains the second major cause of death due to medical causes in the United States of America as well as in much of the developed world (Weir et al., 2003). Clearly, there is an urgent need for new, efficacious and specific anti-cancer approaches (Guillemard and Saragovi, 2004). Virus-based anti-cancer gene therapies, based on the ability of adenoviral or retroviral vectors to deliver suicide genes to cancer cells (Rainov and Ren, 2003), or to kill tumor cells directly (“virolytic therapy”; Everts and van der Poel, 2005, Mathis et al., 2005), are being tested in various clinical trials (www4.od.nih.gov/oba/rac/protocol.pdf). However, although one viral-based vector has been recently approved for the treatment of head and neck cancer, the outcome of several viral-based clinical trials has raised serious concerns regarding the efficacy and safety of such approaches, highlighting the need to develop alternative strategies (Hacein-Bey-Abina et al., 2003a, Hacein-Bey-Abina et al., 2003b, Raper et al., 2003, Williams and Baum, 2003, Glover et al., 2005, Young et al., 2006). Here we discuss the possibility of using recently identified tumor cell-specific nuclear targeting sequences (tNTSs) as tools for enhancing non-viral drug or suicide gene delivery to the nucleus of cancer cells. 2. Nuclear delivery mechanisms A useful strategy in anti-cancer therapy is the specific delivery of high levels of either a suicide gene or a drug (see Box 1) to malignant cells, without affecting healthy cells and tissues. Viral-based vehicles represent the best option in terms of the efficiency of delivery, as viruses have evolved very specific mechanisms to deliver genetic material and proteins to host cells (Fig. 1). Box 1 Herpes simplex virus thymidine kinase as a suicide gene A suicide gene programs cells to kill themselves under certain circumstances, such as upon administration of an inactive prodrug which can be processed to a toxic form. One of the most widely used suicide genes is the Herpes simplex virus 1 (HSV-1) thymidine kinase (TK). HSV-1 TK differs considerably from the human cellular TK in its substrate specificity, phosphorylating a broad spectrum of pyrimidine and purine nucleoside analogues (Pilger et al., 1999), including ganciclovir (GCV). HSV-1 but not human TK phosphorylates GCV to its monophosphate form, which is subsequently converted to the triphosphorylated derivative by cellular kinases. The active triphosphorylated metabolite is then incorporated into the newly synthetized DNA chain, thereby blocking DNA replication. Thus, HSV-1 TK is essential for GCV-induced cellular toxicity, and GCV is one of the most widely used antiviral drugs for treatment of viral infections (De Clercq, 2004). Because of its unique properties, the HSV-1 TK gene has been widely used as a suicide gene in gene therapy vectors (Vassaux and Martin-Duque, 2004). Photodynamic therapy Photodynamic therapy (PDT) is based on the ability of photosentitizers (PSs) such as chlorin e6, to generate singlet oxygen species in response to light exposure. PSs preferentially accumulate in tumor cells but also in some normal tissues such the skin (Jori, 1996), and their action is strongly dependent on their localization inside the target cell, as their cytotoxic action does not exceed 40 nm from the site of activation (Sobolev et al., 2000). To increase their specificity, PSs can be directly administrated into the tumoral mass, in combination with direct light exposure (Sharman et al., 1999). PDT has been proven to be effective for the treatment of some cancers (Wiedmann et al., 2003), with the nucleus being the most sensitive subcellular compartment (Peng et al., 1996). For this reason, development of methods to increase PS targeting to the nucleus of tumor cells is desirable (Bisland et al., 1999, Sobolev et al., 2000). Viruses can interact with the host cell via specific interaction of viral proteins with cellular receptors exposed on the extracellular surface of the cellular plasma membrane (PM; see Fig. 1.1). In the case of non-enveloped DNA viruses such as members of the Adenoviridae family, the virus can be internalized by the cells through an endocytotic mechanism subsequent to receptor binding (see Fig. 1.2). Receptor-mediated endocytosis usually leads to degradation of the internalized ligand in the lysosomal pathway, but certain viral proteins undergo conformational changes under the acid conditions of the endosome to disrupt the vesicular membrane and facilitate the release of the viral particles into the cytoplasm of the host cell (see Fig. 1.3; Seth, 1994). In the case of most DNA viruses and retroviruses, the viral genome is ultimately translocated into the nucleus of the host cell (see Fig. 1.4), in order to be expressed and replicated, or integrated into the host genome in the case of retroviruses. The eukaryotic cell nucleus is separated from the rest of the cell by a double membrane structure – the nuclear envelope (NE) – the only passage through which is represented by the c. 120MDa, multiprotein-constituted nuclear pore complexes (NPCs). Molecules with a mass of <50kDa can freely diffuse through the aqueous channel delimited by the NPC, whereas nucleocytoplasmic transport of larger molecules is an active process mediated by members of the importin (IMP) superfamily of soluble cellular transporters, which can be of α and β types (Weis, 1998). Members of the IMP family recognize specific targeting signals on cargoes, named nuclear localization signals (NLSs) or nuclear export signals (NESs) for transport in the import and export directions, respectively (Fig. 2). NLSs and NESs were first identified on viral proteins: the first NLS characterized, the highly basic 7 amino acid sequence (PKKKRKV132), was from the large tumor antigen (T-Ag) from Simian Virus SV40 (Kalderon et al., 1984), whereas a strongly hydrophobic 11 amino acid stretch (LQLPPLERLTL83), from the human immunodeficency virus 1 (HIV-1) Rev protein was the first NES described (Meyer et al., 1996). The best-characterized nuclear import pathway is that mediated by the IMPα/β heterodimer, where IMPα recognizes the NLS (such as that of T-Ag) on the cargo protein, and IMPβ mediates the docking of the complex to the NPC (see Fig. 2, left; Weis, 1998). IMPβ itself, or one of its many homologues, is also able to interact directly with specific cargoes independently of IMPα. Subsequently the IMP-cargo complex is translocated to the nuclear side of the NPC, where binding of the guanidine nucleotide binding protein Ran in activated GTP-bound form to IMPβ results in the release of the cargo into the nucleus. Certain IMPβ homologues mediate nuclear protein export, the best known being CRM-1 (Fukuda et al., 1997), whose function can be inhibited specifically by the drug leptomycin B (LMB; see Fig. 2, right; Kudo et al., 1998). The three functions described above – cell targeting (CT), endosomal escape (EE), and nuclear targeting (NT; see Fig. 1) – are desirable elements of an efficient cancer-specific targeting agent (Glover et al., 2005). Modular recombinant transporters, assemblies of independently acting domains able to fulfill some or all of these functions (see Table 1 and Fig. 1), have been shown to be capable of targeting reporter genes or drugs specifically to cancer cells in culture (see below; Rosenkranz et al., 2003). That modular transporters of this type may be suitable for targeted delivery in the clinic in the future is indicated by the observation that liver-targeted luciferase expression has been achieved in mice after intravenous injection of a modular transporter complexed with plasmid DNA (Nishikawa et al., 2000). | a opT-NLS, Simian Virus 40 large tumor antigen (T-Ag) derived sequence CGPGSDDEAAADAQHAAPPKKKRKVGY; T-Ag NLS, T-Ag derived sequence PKKKRKVEDPYC; α-MSH, Melanocyte stimulating hormone; DT TD, Diphteria toxin translocation domain; EGF, epidermal growth factor; A124SV40LTa, T-Ag derived sequence APPKKKRKVEDP. bNLSV404 peptide, Simian virus SV40 large tumor antigen (T-ag) derived sequence PKKKRKVGPKKKRKVGPKKKRKVGPKKKRKVGC; GAL4 BD, Saccharomyces cerevisiae GAL4 DNA binding domain; scFv(FRP5), antibody fragment specific for the tumor-associated ErbB2 antigen; DT TD, Diptheria toxin translocation domain; PE TD, Pseudomonas exotoxin translocation domain; TGF-α, Transforming growth factor alpha; FMDV, Foot-and-mouth disease virus; α-MSH, Melanocyte stimulating hormone; T-Ag NLS, T-Ag derived sequence PKKKRKVEDPYC; OpT-NLS, T-Ag derived sequence CGPGSDDEAAADAQHAAPPKKKRKVGY. cAn NLS has been described within the GAL4 BD (Silver et al., 1984, Chan et al., 1998; Chan and Jans, 1999a, Chan and Jans, 1999b). dA cryptic NLS has been described within the β-Gal (McInnis et al., 1995). |
3. Importance of nuclear delivery of modular transporters Several studies have shown that the efficiency of foreign gene expression depends on the ability of the modular transporter to deliver the coding sequences to the nucleus of the target cells and that addition of NT modules can improve gene expression (Chan et al., 2000, Chan and Jans, 1999a, Chan and Jans, 1999b, Chan and Jans, 2001, Chan and Jans, 2002). For example, Villaverde and coworkers described a modular protein (249AL) comprising the β-galactosidase (β-Gal) protein as a carrier, a N-terminal polylysine stretch as a DNA compacting and protecting module, and the foot-and-mouth disease virus (FMDV) RGD sequence as a CT module able to interact with cell surface integrins. 249AL is able to associate with a firefly luciferase expressing plasmid without undergoing any appreciable diminution of β-Gal enzymatic activity and can facilitate expression of the luciferase reporter in integrin-expressing CaCO2 cells with an efficiency comparable to that of a non-targeted liposome-based commercial transfection system (Aris et al., 2000). Subsequent inclusion of an NT module by adding the T-Ag NLS, generated the NLSCt protein which transfected CaCO2 cells with 30-fold higher efficiency than that of 249AL. The implication is that the efficiency of transgene expression can be facilitated by increasing the nuclear delivery of the transgene (Aris and Villaverde, 2003). Intranuclear delivery is also important for cellular transporters designed to deliver photosentitizing (PS) agents to cancer cells (see Box 1). Using bovine serum albumin (BSA) as a carrier linked to insulin as a CT module, Sobolev and coworkers (Akhlynina et al., 1993, Akhlynina et al., 1995) generated a modular targeting protein able to specifically deliver conjugated clorin e6 to the human hepatoma cell line PLC/PRF/5, resulting in reduction of the EC50 by about 100-fold when compared to that of free clorin e6 after light exposure. Interestingly, addition of a functional “optimized” T-Ag NLS (opT-NLS) as an NT module significantly decreased the EC50 about 7-fold, compared to a functionally impaired NLS mutant derivative (Akhlynina et al., 1997). Finally, addition of an EE moiety in the form of adenovirus particles mixed with the modular transporter further enhanced the efficiency (Akhlynina et al., 1999). These and other studies show that the addition of an NT module to a modular transporter significantly enhances the efficacy of both gene transfer (Chan et al., 1998, Chan et al., 2000, Chan and Jans, 1999a, Chan and Jans, 1999b, Chan and Jans, 2001, Singh et al., 1999, Aris and Villaverde, 2003, Ritter et al., 2003) and sensitivity of target cells to nuclear acting toxic agents such as PSs (Akhlynina et al., 1997, Akhlynina et al., 1999, Bisland et al., 1999, Brokx et al., 2002; see also Table 1). 4. Tumor cell-specific nuclear delivery Several proteins, including TRAIL, Adenovirus E4orf4 and the Chicken Anemia Virus protein 3 (VP3, also known as Apoptin) have been shown to kill tumor cells selectively (Danen-van Oorschot et al., 1997, Lavoie et al., 1998, Walczak et al., 1999), raising great hopes for their utilization in anti-cancer therapy (Branton and Roopchand, 2001, MacFarlane, 2003, Rohn and Noteborn, 2004, Tavassoli et al., 2005). While nuclear localization is important, but not essential, for E4orf4 mediated induction of apoptosis (Miron et al., 2004), VP3's ability to kill tumor cells selectively is correlated with its nuclear localization specifically in tumor and not “normal” cells (Danen-van Oorschot et al., 2003). VP3 is a 121-amino acid protein rich in Ser and Thr residues, which induces programmed cell death (PCD) in chicken thymocytes (Noteborn et al., 1994), and in several human tumor but not normal cells, through a p53-independent, Bcl-2-resistant process (Zhuang et al., 1995). However, its ability to induce PCD in primary human fibroblasts has been reported recently (Guelen et al., 2004), suggesting that further studies are required to verify VP3's selectivity in terms of tumor cell killing. Although not completely understood, the molecular basis of VP3's tumor-specific nuclear localization has been intensively investigated (Oro and Jans, 2004, Wang et al., 2004, Poon et al., 2005a, Poon et al., 2005b, Rohn et al., 2005, Wagstaff and Jans, 2006). Regardless of its proapoptotic activity, understanding of the mechanisms and sequences responsible for VP3's tumor-cells specific nuclear localization would allow use of the latter as an NT module in modular transporters designed to specifically localize specifically in the nucleus of tumor but not normal cells. The determinants of VP3 intracellular localization thus far characterized (see Fig. 3, Fig. 4) are: 1.A bipartite basic NLS, located at the C-terminus of the protein (aa 80-121), necessary for VP3 nuclear accumulation as revealed by analysis of deletion and point mutant derivatives (Danen-van Oorschot et al., 1997, Danen-van Oorschot et al., 2003, Wang et al., 2004, Poon et al., 2005a, Poon et al., 2005b). This motif is able to confer nuclear localization on heterologous proteins such as green fluorescent protein (GFP; Danen-van Oorschot et al., 2003, Wadia et al., 2004, Poon et al., 2005a, Poon et al., 2005b) and maltose-binding protein (MBP; Rohn et al., 2005). Intriguingly, VP3(74–121) binds to IMPβ1 with three times higher affinity compared to VP3(1–121), suggesting that the NLS of VP3 activity may be regulated by intramolecular masking through the VP3 N-terminus (Wagstaff and Jans, 2006). 2.A CRM-1 recognized NES (residues 97–105) inactive in tumor cells, which contributes to determine tumor cell-specificity of VP3 localization (Poon et al., 2005a). The NES is located between the arms of the bipartite NLS, and thus aa 74–121, encompassing both the VP3 NLS and NES, represent a tNTS. 3.VP3 T108, adjacent to the NES, is specifically phosphorylated by an unidentified kinase in tumor but not normal cells (Rohn et al., 2002). Phosphorylation at this site appears to be responsible for tumor cell-specificity of VP3 nuclear localization, by inhibiting NES-mediated nuclear export in tumor cells (Poon et al., 2005a), and possibly also by enhancing its nuclear import (Rohn et al., 2002, Rohn et al., 2005). The phosphomimetic E108 VP3 mutant derivative shows enhanced nuclear localization in normal cells, reaching levels of nuclear accumulation comparable to that achieved in tumor cells (Poon et al., 2005a), but is not responsive to LMB treatment, consistent with the idea that phosphorylation at T108 primarily inhibits NES activity. 4.A leucine-rich sequence (LRS), at residues 33–46, which appears to mediate VP3'S interaction with the promyelocytic leukemia (PML) protein (Poon et al., 2005a), the organizer of the PML nuclear bodies (PML NBs). PML NBs are structured protein complexes associated with the nuclear matrix, associated with several functions such as apoptosis, DNA replication and repair, transcription regulation and RNA transport (Takahashi et al., 2004). The LRS lies within the VP3 multimerization domain (residues 26–69; Leliveld et al., 2003a), and although proposed to be a putative NES (Danen-van Oorschot et al., 1997), this has been disproved (Wang et al., 2004, Poon et al., 2005a). Intriguingly, mutation of the LRS sequence not only ablates VP3 co-localization with PML, but also reduces VP3 nuclear accumulation in tumor and normal cells, and LMB responsiveness in normal cells. Thus, association with PML and thereby PML NBs may be a prerequisite for VP3 nuclear export (Poon et al., 2005a). VP3 has also been reported to bind to other nuclear components such as the kinase HIPK2 (Poon et al., 2005a), the human death effector domain-associated factor (Danen-van Oorschot et al., 2004), DNA (Leliveld et al., 2003b) and APC-1, a subunit of the anaphase-promoting complex/cyclosome involved in the assembly and regulation of the cyclosome complex (Teodoro et al., 2004). VP3 has also been reported to interact with cytoplasmic protein Hippi, the protein interactor of the Huntingtin interacting protein 1 (Hip-1; Cheng et al., 2003). Thus, it seems possible that VP3 subcellular localization stems from several, competing processes within the cell such as nuclear and cytoplasmic retention as well as facilitated nuclear import and export. As mentioned above, modular transporters ideally combine CT, EE and NT functions in order achieve efficient delivery of drugs or DNA encoding toxic genes to the nuclei of target cancer cells. Importantly, VP3(74–121) not only exhibits tumor cell-specific nuclear localization (Poon et al., 2005a, Poon et al., 2005b), but has been reported to induce apoptosis in cancer cells (Danen-van Oorschot et al., 2003), as well as bind DNA (Leliveld et al., 2004), raising the possibility that this portion of VP3 could possess DNA binding, tumor cell-specific nuclear targeting and proapoptotic abilities. Further analysis is required to demonstrate if this is the case. 5. Tumor cell-specific phosphorylation Studies on VP3 suggest the existence of tumor-specific cell-phosphorylation activity (Rohn et al., 2002, Zhang et al., 2004). A number of kinases show elevated activity in transformed cells. Protein kinase CK2 (CK2), is activated to up to 7-fold higher levels in tumor than in normal cells (Guerra and Issinger, 1999, Tawfic et al., 2001); while cytoplasmic extracts of cells obtained from SCCHN tumor surgical specimens show a 6-fold higher CK2 activity compared to those of cells obtained from normal oropharyngeal mucosa (Faust et al., 1999). These findings are interesting in light of the fact that CK2 facilitates the nuclear accumulation of a number of proteins, mainly through regulation of the NLS activity of a conserved modular domain known as the CcN motif (Rihs et al., 1991, Ueda et al., 1995, Longshaw et al., 2000, Briggs et al., 2001, Nuthall et al., 2002, Wilson et al., 2002, Alvisi et al., 2005). The CcN (CK2, cdc, and NLS) motif is a modular domain, originally described for T-Ag, that comprises phosphorylation sites for both CK2 and cyclin-dependent kinases (cdks) upstream of the NLS (Jans et al., 1991, Rihs et al., 1991). A phosphorylation site for double-stranded DNA-dependent kinase (dsDNA-PK) upstream of the cdk site has also been identified (Xiao et al., 1997). In vitro experiments indicate that CK2-mediated phosphorylation of Ser 111/112 increases the rate of nuclear accumulation of T-Ag-CcN-containing fusion proteins (Rihs et al., 1991), by increasing the affinity of recognition by IMPα/β (Hubner et al., 1997). Phosphorylation of Thr124 by cdk34 inhibits the nuclear import process (Jans et al., 1991), while dsDNA-PK mediated phosphorylation of Ser 120 enhances the maximal level of nuclear import and promotes IMPα/β binding in synergy with the CK2 site (Xiao et al., 1997). These data enabled to the development of a 25-amino acid optimized T-Ag NLS (opT-NLS), which has been used as an NT module in recombinant modular transporters for the specific targeting of PS agents to cancer cells to increase cell killing (Akhlynina et al., 1997, Akhlynina et al., 1999, Rosenkranz et al., 2003), or in recombinant modular transporter to increase reporter gene expression (Chan and Jans, 1999a, Chan and Jans, 1999b, Chan and Jans, 2001, Chan and Jans, 2002). Since CK2 is highly active in tumor cells as indicated above (Faust et al., 1999), the opT-NLS itself effectively represents a tNTS, at least for tumors showing high CK2 activity. Clearly, further studies are required to verify this interesting possibility using the approaches described by Poon et al., 2005a, Poon et al., 2005b. 6. Engineering the T-Ag CcN motif to generate a tNTS The T-Ag CcN motif has been extensively studied, with the molecular mechanisms underlying the regulation of its activity well characterized (Jans et al., 1991, Rihs et al., 1991, Hubner et al., 1997, Xiao et al., 1997, Xiao et al., 1998, Fontes et al., 2003). The introduction of point mutations substituting the CK2 consensus phosphorylatin site with consensus sites for cAMP-dependent protein kinase (PKA) or Ca2+, phospholipid-dependent protein kinase (PKC) within the CcN motif, results in enhanced nuclear accumulation of β-GAL, in response to agents elevating the intracellular cAMP or activating PKC, respectively, when tested in an in vitro transport assay or in microinjected cells (Xiao et al., 1996, Xiao et al., 1998). This demonstrates that the CK2 site within the CcN motif can be substituted by sites for other kinases and yet retain functionality in terms of nuclear localization in response to specific phosphorylation; changing the kinase site changes the cellular signal that potentially drives nuclear localization. Substitution of the CK2 site with a potentially cancer-specific phosphorylation site could generate a novel specific tNTS. Screening for sequences that are selectively phosphorylated in the cytoplasm of tumor as opposed to normal cells may identify sequences that enhance tumor specificity of modular transporters for the delivery to cancer cells of suicide genes, or PS agents or other nuclear-acting drugs. 7. Conclusions and future directions Strategies to achieve cancer cell-specific targeting – whether at the level of the whole cell, or more specifically at the level of nuclear transport – are obviously limited by the fact that cancer cells are derived from normal cells, implying that much of the fundamental signaling and transport apparatus is shared between cancer and normal cells. Hence, despite results for VP3 and other proteins discussed here, the idea that a targeting signal or approach could be uniquely functional in terms of targeting tumor as opposed to normal cells is probably naïve. As alluded above, however, it is clear that there are several quantitative differences between cancer and normal cells in the levels of expression and activation of different signaling molecules, including protein kinases, and even in the levels of nuclear transport components (Kau et al., 2004, Poon and Jans, 2005). The ideal strategy for pursuing cancer cell-specific targeting might therefore be to exploit as many quantitative differences between tumor and normal cells as possible, and use them in combination to achieve a cumulative effect, so that much higher concentrations of drug or suicide gene are achieved in tumor as opposed to normal cells. The VP3 tNTS is clearly one targeting component that is much more efficient in conferring nuclear accumulation in tumor than in normal cells, but this appears to be a quantitative rather than all-or-nothing effect, and hence needs to be used in combination with other “tumor cell-enriched pathways” (e.g. phosphorylation cascades, receptor expression, endocytotic pathways, etc.; Guillemard and Saragovi, 2004) to achieve the equivalent of a “tumor cell-specific” effect. This can also be combined with further levels of “enrichment” such as cell/tissue-specific promoters for gene therapeutic approaches, and localized photoactivation in the case of the use of PSs in PDT. The VP3 tNTS and modifications thereof, as well as strategies inspired by the idea of tumor cell-specific phosphorylation (see above), are great steps towards the long-term aim of cancer cell-specific therapies that do not kill or damage normal cells/tissue. Clearly, however, the key will be to find other tumor cell-specific acting moieties to use in combination with these sequences. With concerted effort, the ultimate end may be in sight, not so much of a “magic bullet” perhaps, but of a multi-component entity comprising multiple “semi-magic” moieties with higher activity in tumor than in normal cells. In combination, these cancer cell hyperactive components should afford a cumulative effect to achieve the ultimate end of efficient and above all specific tumor cell killing. 8. Summary •Modular recombinant transporters, assemblies of independently acting domains, have been shown to be capable of targeting reporter genes or drugs to cancer cells specifically through cellular targeting (CT) modules. •The addition of a nuclear targeting (NT) module increases the ability of modular transporters to deliver suicide genes or drugs to the nucleus of the target cell. •VP3 is a protein that shows tumor cell-specific nuclear targeting as mediated by a phosphorylation regulated tumor-specific nuclear targeting sequence (tNTS). •The activity of the best characterized nuclear targeting signal, the nuclear localization signal (NLS) from Simian virus SV40 large tumor antigen (T-Ag), is increased by protein kinase CK2 (CK2) phosphorylation upstream of the NLS. •CK2 activity is elevated in several cancer cells so that T-Ag NLS-based modular transporters may be promising for therapy where tumors show elevated CK2 activity. •Substitution of the CK2 site of T-Ag with consensus sites for kinases such Ca2+, phospholipid-dependent protein kinase (PKC) or cAMP-dependent protein kinase (PKA) results in its activity being increased by PKC and PKA activators, respectively. It is possible to generate tNTSs by inserting sequences phosphorylated in the cytoplasm of tumor but not normal cells in place of the T-Ag CK2 site. •The combination of several tumor cell-specific modules, including CT and NT would increase the specificity of delivery to tumor cells of suicide genes or nuclear-acting drugs. Acknowledgments This work was supported by the Anti-Cancer Council of Victoria and the Australian National Health and Medical Research Council (fellowship #384109). References Akhlynina et al., 1993. 1.Akhlynina TV, Rosenkranz AA, Jans DA, Gulak PV, Serebryakova NV, Sobolev AS. The use of internalizable derivatives of chlorin E6 for increasing its photosensitizing activity. Photochem. Photobiol. 1993;58:45–48. MEDLINE |
CrossRef
Akhlynina et al., 1995. 2.Akhlynina TV, Rosenkranz AA, Jans DA, Sobolev AS. Insulin-mediated intracellular targeting enhances the photodynamic activity of chlorin e6. Cancer Res. 1995;55:1014–1019. MEDLINE Akhlynina et al., 1997. 3.Akhlynina TV, Jans DA, Rosenkranz AA, Statsyuk NV, Balashova IY, Toth G, et al. Nuclear targeting of chlorin e6 enhances its photosensitizing activity. J. Biol. Chem. 1997;272:20328–20331. MEDLINE |
CrossRef
Akhlynina et al., 1999. 4.Akhlynina TV, Jans DA, Statsyuk NV, Balashova IY, Toth G, Pavo I, et al. Adenoviruses synergize with nuclear localization signals to enhance nuclear delivery and photodynamic action of internalizable conjugates containing chlorin e6. Int. J. Cancer. 1999;81:734–740. MEDLINE |
CrossRef
Alvisi et al., 2005. 5.Alvisi G, Jans DA, Guo J, Pinna LA, Ripalti A. A protein kinase CK2 site flanking the nuclear targeting signal enhances nuclear transport of human cytomegalovirus ppUL44. Traffic. 2005;6:1002–1013. MEDLINE |
CrossRef
Aris et al., 2000. 6.Aris A, Feliu JX, Knight A, Coutelle C, Villaverde A. Exploiting viral cell-targeting abilities in a single polypeptide, non-infectious, recombinant vehicle for integrin-mediated DNA delivery and gene expression. Biotechnol. Bioeng. 2000;68:689–696. MEDLINE |
CrossRef
Aris and Villaverde, 2003. 7.Aris A, Villaverde A. Engineering nuclear localization signals in modular protein vehicles for gene therapy. Biochem. Biophys. Res. Commun. 2003;304:625–631.
CrossRef
Bisland et al., 1999. 8.Bisland SK, Singh D, Gariepy J. Potentiation of chlorin e6 photodynamic activity in vitro with peptide-based intracellular vehicles. Bioconjug. Chem. 1999;10:982–992. MEDLINE |
CrossRef
Box et al., 2003. 9.Box M, Parks DA, Knight A, Hale C, Fishman PS, Fairweather NF. A multi-domain protein system based on the HC fragment of tetanus toxin for targeting DNA to neuronal cells. J. Drug Target. 2003;11:333–343.
CrossRef
Branton and Roopchand, 2001. 10.Branton PE, Roopchand DE. The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene. 2001;20:7855–7865. MEDLINE |
CrossRef
Briggs et al., 2001. 11.Briggs LJ, Johnstone RW, Elliot RM, Xiao CY, Dawson M, Trapani JA, et al. Novel properties of the protein kinase CK2-site-regulated nuclear- localization sequence of the interferon-induced nuclear factor IFI 16. Biochem. J. 2001;353:69–77. MEDLINE |
CrossRef
Brokx et al., 2002. 12.Brokx RD, Bisland SK, Gariepy J. Designing peptide-based scaffolds as drug delivery vehicles. J. Control. Release. 2002;78:115–123. MEDLINE |
CrossRef
Chan et al., 1998. 13.Chan CK, Hubner S, Hu W, Jans DA. Mutual exclusivity of DNA binding and nuclear localization signal recognition by the yeast transcription factor GAL4: implications for nonviral DNA delivery. Gene Ther. 1998;5:1204–1212. MEDLINE Chan and Jans, 1999a. 14.Chan CK, Jans DA. Enhancement of polylysine-mediated transferrinfection by nuclear localization sequences: polylysine does not function as a nuclear localization sequence. Hum. Gene Ther. 1999;10:1695–1702. MEDLINE Chan and Jans, 1999b. 15.Chan CK, Jans DA. Synergy of importin alpha recognition and DNA binding by the yeast transcriptional activator GAL4. FEBS Lett. 1999;462:221–224. Abstract | Full Text |
Full-Text PDF (172 KB)
|
CrossRef
Chan et al., 2000. 16.Chan CK, Senden T, Jans DA. Supramolecular structure and nuclear targeting efficiency determine the enhancement of transfection by modified polylysines. Gene Ther. 2000;7:1690–1697. MEDLINE |
CrossRef
Chan and Jans, 2001. 17.Chan CK, Jans DA. Enhancement of MSH receptor- and GAL4-mediated gene transfer by switching the nuclear import pathway. Gene Ther. 2001;8:166–171. MEDLINE |
CrossRef
Chan and Jans, 2002. 18.Chan CK, Jans DA. Using nuclear targeting signals to enhance non-viral gene transfer. Immunol. Cell Biol. 2002;80:119–130. MEDLINE |
CrossRef
Chen et al., 1995. 19.Chen SY, Zani C, Khouri Y, Marasco WA. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther. 1995;2:116–123. MEDLINE Cheng et al., 2003. 20.Cheng CM, Huang SP, Chang YF, Chung WY, Yuo CY. The viral death protein Apoptin interacts with Hippi, the protein interactor of Huntingtin-interacting protein 1. Biochem. Biophys. Res. Commun. 2003;305:359–364.
CrossRef
Danen-van Oorschot et al., 1997. 21.Danen-van Oorschot AA, Fischer DF, Grimbergen JM, Klein B, Zhuang S, Falkenburg JH, et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc. Natl. Acad. Sci. U.S.A. 1997;94:5843–5847. MEDLINE |
CrossRef
Danen-van Oorschot et al., 2003. 22.Danen-van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, et al. Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J. Biol. Chem. 2003;278:27729–27736. MEDLINE |
CrossRef
Danen-van Oorschot et al., 2004. 23.Danen-van Oorschot AA, Voskamp P, Seelen MC, van Miltenburg MH, Bolk MW, Tait SW, et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death Differ. 2004;11:564–573. MEDLINE |
CrossRef
De Clercq, 2004. 24.De Clercq E. Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2004;2:704–720. MEDLINE |
CrossRef
Everts and van der Poel, 2005. 25.Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005;12:141–161. MEDLINE |
CrossRef
Faust et al., 1999. 26.Faust RA, Niehans G, Gapany M, Hoistad D, Knapp D, Cherwitz D, et al. Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int. J. Biochem. Cell. Biol. 1999;31:941–949. MEDLINE |
CrossRef
Fominaya et al., 1998. 27.Fominaya J, Uherek C, Wels W. A chimeric fusion protein containing transforming growth factor-alpha mediates gene transfer via binding to the EGF receptor. Gene Ther. 1998;5:521–530. MEDLINE Fominaya and Wels, 1996. 28.Fominaya J, Wels W. Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system. J. Biol. Chem. 1996;271:10560–10568. MEDLINE |
CrossRef
Fontes et al., 2003. 29.Fontes MR, Teh T, Toth G, John A, Pavo I, Jans DA, et al. Role of flanking sequences and phosphorylation in the recognition of the simian-virus-40 large T-antigen nuclear localization sequences by importin-alpha. Biochem. J. 2003;375:339–349.
CrossRef
Fortunati et al., 2000. 30.Fortunati E, Ehlert E, van Loo ND, Wyman C, Eble JA, Grosveld F, et al. A multi-domain protein for beta1 integrin-targeted DNA delivery. Gene Ther. 2000;7:1505–1515. MEDLINE |
CrossRef
Fukuda et al., 1997. 31.Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M, et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 1997;390:308–311. MEDLINE |
CrossRef
Gaur et al., 2002. 32.Gaur R, Gupta PK, Goyal A, Wels W, Singh Y. Delivery of nucleic acid into mammalian cells by anthrax toxin. Biochem. Biophys. Res. Commun. 2002;297:1121–1127.
CrossRef
Gijsens et al., 2000. 33.Gijsens A, Missiaen L, Merlevede W, de Witte P. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. Cancer Res. 2000;60:2197–2202. MEDLINE Glover et al., 2005. 34.Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat. Rev. Genet. 2005;6:299–310. MEDLINE |
CrossRef
Guelen et al., 2004. 35.Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene. 2004;23:1153–1165. MEDLINE |
CrossRef
Guerra and Issinger, 1999. 36.Guerra B, Issinger OG. Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis. 1999;20:391–408. MEDLINE |
CrossRef
Guillemard and Saragovi, 2004. 37.Guillemard V, Saragovi HU. Novel approaches for targeted cancer therapy. Curr. Cancer Drug Targets. 2004;4:313–326. MEDLINE |
CrossRef
Hacein-Bey-Abina et al., 2003a. 38.Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003;348:255–256.
CrossRef
Hacein-Bey-Abina et al., 2003b. 39.Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415–419.
CrossRef
Hubner et al., 1997. 40.Hubner S, Xiao CY, Jans DA. The protein kinase CK2 site (Ser111/112) enhances recognition of the simian virus 40 large T-antigen nuclear localization sequence by importin. J. Biol. Chem. 1997;272:17191–17195. MEDLINE |
CrossRef
Jans et al., 1991. 41.Jans DA, Ackermann MJ, Bischoff JR, Beach DH, Peters R. p34cdc2-mediated phosphorylation at T124 inhibits nuclear import of SV-40 T antigen proteins. J. Cell Biol. 1991;115:1203–1212. MEDLINE |
CrossRef
Jori, 1996. 42.Jori G. Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy. J. Photochem. Photobiol. B. 1996;36:87–93. MEDLINE |
CrossRef
Kalderon et al., 1984. 43.Kalderon D, Richardson WD, Markham AF, Smith AE. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature. 1984;311:33–38. MEDLINE |
CrossRef
Kau et al., 2004. 44.Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat. Rev. Cancer. 2004;4:106–117. Kudo et al., 1998. 45.Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y, Yanagida M, et al. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp. Cell Res. 1998;242:540–547. MEDLINE |
CrossRef
Lavoie et al., 1998. 46.Lavoie JN, Nguyen M, Marcellus RC, Branton PE, Shore GC. E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk. J. Cell Biol. 1998;140:637–645. MEDLINE |
CrossRef
Leliveld et al., 2003a. 47.Leliveld SR, Zhang YH, Rohn JL, Noteborn MH, Abrahams JP. Apoptin induces tumor-specific apoptosis as a globular multimer. J. Biol. Chem. 2003;278:9042–9051. MEDLINE |
CrossRef
Leliveld et al., 2003b. 48.Leliveld SR, Dame RT, Mommaas MA, Koerten HK, Wyman C, Danen-van Oorschot AA, et al. Apoptin protein multimers form distinct higher-order nucleoprotein complexes with DNA. Nucleic Acids Res. 2003;31:4805–4813.
CrossRef
Leliveld et al., 2004. 49.Leliveld SR, Dame RT, Rohn JL, Noteborn MH, Abrahams JP. Apoptin's functional N- and C-termini independently bind DNA. FEBS Lett. 2004;557:155–158. Abstract | Full Text |
Full-Text PDF (179 KB)
|
CrossRef
Liu and Hamblin, 2005. 50.Liu Q, Hamblin MR. Macrophage-targeted photodynamic therapy: scavenger receptor expression and activation state. Int. J. Immunopathol. Pharmacol. 2005;18:391–402. MEDLINE Longshaw et al., 2000. 51.Longshaw VM, Dirr HW, Blatch GL, Lassle M. The in vitro phosphorylation of the co-chaperone mSTI1 by cell cycle kinases substantiates a predicted casein kinase II-p34cdc2-NLS (CcN) motif. Biol. Chem. 2000;381:1133–1138. MEDLINE |
CrossRef
Lutsenko et al., 1999. 52.Lutsenko SV, Feldman NB, Finakova GV, Posypanova GA, Severin SE, Skryabin KG, et al. Targeting phthalocyanines to tumor cells using epidermal growth factor conjugates. Tumour Biol. 1999;20:218–224. MEDLINE |
CrossRef
MacFarlane, 2003. 53.MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol. Lett. 2003;139:89–97. MEDLINE |
CrossRef
Mathis et al., 2005. 54.Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene. 2005;24:7775–7791. MEDLINE |
CrossRef
McInnis et al., 1995. 55.McInnis R, Perkinson RA, Kuo BA, Norton PA. Unexpected nuclear localization of a chimeric beta-galactosidase lacZ reporter gene product in mammalian cells. Biochem. Mol. Biol. Int. 1995;36:483–490. MEDLINE Medina-Kauwe et al., 2001a. 56.Medina-Kauwe LK, Kasahara N, Kedes L. 3PO, a novel nonviral gene delivery system using engineered Ad5 penton proteins. Gene Ther. 2001;8:795–803. MEDLINE |
CrossRef
Medina-Kauwe et al., 2001b. 57.Medina-Kauwe LK, Maguire M, Kasahara N, Kedes L. Nonviral gene delivery to human breast cancer cells by targeted Ad5 penton proteins. Gene Ther. 2001;8:1753–1761. MEDLINE |
CrossRef
Meyer et al., 1996. 58.Meyer BE, Meinkoth JL, Malim MH. Nuclear transport of human immunodeficiency virus type 1, visna virus, and equine infectious anemia virus Rev proteins: identification of a family of transferable nuclear export signals. J. Virol. 1996;70:2350–2359. Miron et al., 2004. 59.Miron MJ, Gallouzi IE, Lavoie JN, Branton PE. Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death. Oncogene. 2004;23:7458–7468. MEDLINE |
CrossRef
Nishikawa et al., 2000. 60.Nishikawa M, Yamauchi M, Morimoto K, Ishida E, Takakura Y, Hashida M. Hepatocyte-targeted in vivo gene expression by intravenous injection of plasmid DNA complexed with synthetic multi-functional gene delivery system. Gene Ther. 2000;7:548–555. MEDLINE |
CrossRef
Noteborn et al., 1994. 61.Noteborn MH, Todd D, Verschueren CA, de Gauw HW, Curran WL, Veldkamp S, et al. A single chicken anemia virus protein induces apoptosis. J. Virol. 1994;68:346–351. Nuthall et al., 2002. 62.Nuthall HN, Joachim K, Palaparti A, Stifani S. A role for cell cycle-regulated phosphorylation in Groucho-mediated transcriptional repression. J. Biol. Chem. 2002;277:51049–51057. MEDLINE |
CrossRef
Oro and Jans, 2004. 63.Oro C, Jans DA. The tumour specific pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. Curr. Drug Targets. 2004;5:179–190. MEDLINE |
CrossRef
Paul et al., 1997. 64.Paul RW, Weisser KE, Loomis A, Sloane DL, LaFoe D, Atkinson EM, et al. Gene transfer using a novel fusion protein, GAL4/invasin. Hum. Gene Ther. 1997;8:1253–1262. MEDLINE |
CrossRef
Peng et al., 1996. 65.Peng Q, Moan J, Nesland JM. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct. Pathol. 1996;20:109–129. MEDLINE |
CrossRef
Pilger et al., 1999. 66.Pilger BD, Perozzo R, Alber F, Wurth C, Folkers G, Scapozza L. Substrate diversity of herpes simplex virus thymidine kinase. Impact of the kinematics of the enzyme. J. Biol. Chem. 1999;274:31967–31973. MEDLINE |
CrossRef
Poon and Jans, 2005. 67.Poon IK, Jans DA. Regulation of nuclear transport: central role in development and transformation?. Traffic. 2005;6:173–186. MEDLINE |
CrossRef
Poon et al., 2005a. 68.Poon IK, Oro C, Dias MM, Zhang J, Jans DA. Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res. 2005;65:7059–7064. MEDLINE |
CrossRef
Poon et al., 2005b. 69.Poon IK, Oro C, Dias MM, Zhang JP, Jans DA. A tumor cell-specific nuclear targeting signal within chicken anemia virus VP3/apoptin. J. Virol. 2005;79:1339–1341.
CrossRef
Rainov and Ren, 2003. 70.Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy—what have we learned?. J. Neurooncol. 2003;65:227–236.
CrossRef
Raper et al., 2003. 71.Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003;80:148–158. MEDLINE |
CrossRef
Rihs et al., 1991. 72.Rihs HP, Jans DA, Fan H, Peters R. The rate of nuclear cytoplasmic protein transport is determined by the casein kinase II site flanking the nuclear localization sequence of the SV40 T-antigen. EMBO J. 1991;10:633–639. MEDLINE Ritter et al., 2003. 73.Ritter W, Plank C, Lausier J, Rudolph C, Zink D, Reinhardt D, et al. A novel transfecting peptide comprising a tetrameric nuclear localization sequence. J. Mol. Med. 2003;81:708–717. MEDLINE |
CrossRef
Rohn et al., 2002. 74.Rohn JL, Zhang YH, Aalbers RI, Otto N, Den Hertog J, Henriquez NV, et al. A tumor-specific kinase activity regulates the viral death protein Apoptin. J. Biol. Chem. 2002;277:50820–50827. MEDLINE |
CrossRef
Rohn and Noteborn, 2004. 75.Rohn JL, Noteborn MH. The viral death effector Apoptin reveals tumor-specific processes. Apoptosis. 2004;9:315–322. MEDLINE |
CrossRef
Rohn et al., 2005. 76.Rohn JL, Zhang YH, Leliveld SR, Danen-van Oorschot AA, Henriquez NV, Abrahams JP, et al. Relevance of apoptin's integrity for its functional behavior. J. Virol. 2005;79:1337–1338.
CrossRef
Rosenkranz et al., 2003. 77.Rosenkranz AA, Lunin VG, Gulak PV, Sergienko OV, Shumiantseva MA, Voronina OL, et al. Recombinant modular transporters for cell-specific nuclear delivery of locally acting drugs enhance photosensitizer activity. FASEB J. 2003;17:1121–1123. Seth, 1994. 78.Seth P. Mechanism of adenovirus-mediated endosome lysis: role of the intact adenovirus capsid structure. Biochem. Biophys. Res. Commun. 1994;205:1318–1324.
CrossRef
Sharman et al., 1999. 79.Sharman WM, Allen CM, van Lier JE. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov. Today. 1999;4:507–517.
CrossRef
Silver et al., 1984. 80.Silver PA, Keegan LP, Ptashine M. Amino terminus of the yeast GAL4 gene product is sufficient for nuclear localization. Proc. Natl. Acad. Sci. U.S.A. 1984;81:5951–5955. MEDLINE |
CrossRef
Singh et al., 1999. 81.Singh D, Bisland SK, Kawamura K, Gariepy J. Peptide-based intracellular shuttle able to facilitate gene transfer in mammalian cells. Bioconjug. Chem. 1999;10:745–754. MEDLINE |
CrossRef
Sobolev et al., 2000. 82.Sobolev AS, Jans DA, Rosenkranz AA. Targeted intracellular delivery of photosensitizers. Prog. Biophys. Mol. Biol. 2000;73:51–90. MEDLINE |
CrossRef
Takahashi et al., 2004. 83.Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H. PML nuclear bodies and apoptosis. Oncogene. 2004;23:2819–2824. MEDLINE |
CrossRef
Tavassoli et al., 2005. 84.Tavassoli M, Guelen L, Luxon BA, Gaken J. Apoptin: specific killer of tumor cells?. Apoptosis. 2005;10:717–724.
CrossRef
Tawfic et al., 2001. 85.Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signal in neoplasia. Histol. Histopathol. 2001;16:573–582. MEDLINE Teodoro et al., 2004. 86.Teodoro JG, Heilman DW, Parker AE, Green MR. The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev. 2004;18:1952–1957. MEDLINE |
CrossRef
Ueda et al., 1995. 87.Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 1995;9:41–47. MEDLINE |
CrossRef
Uherek et al., 1998. 88.Uherek C, Fominaya J, Wels W. A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery. J. Biol. Chem. 1998;273:8835–8841. MEDLINE |
CrossRef
Vassaux and Martin-Duque, 2004. 89.Vassaux G, Martin-Duque P. Use of suicide genes for cancer gene therapy: study of the different approaches. Expert Opin. Biol. Ther. 2004;4:519–530. MEDLINE |
CrossRef
Wadia et al., 2004. 90.Wadia JS, Wagner MV, Ezhevsky SA, Dowdy SF. Apoptin/VP3 contains a concentration-dependent nuclear localization signal (NLS), not a tumorigenic selective NLS. J. Virol. 2004;78:6077–6078.
CrossRef
Wagstaff and Jans, 2006. 91.Wagstaff KM, Jans DA. Intramolecular masking of nuclear localization signals: analysis of importin binding using a novel AlphaScreen-based method. Anal. Biochem. 2006;348:49–56. MEDLINE |
CrossRef
Walczak et al., 1999. 92.Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999;5:157–163. MEDLINE |
CrossRef
Wang et al., 2004. 93.Wang QM, Fan GC, Chen JZ, Chen HP, He FC. A putative NES mediates cytoplasmic localization of Apoptin in normal cells. Acta Biochim. Biophys. Sin. (Shanghai). 2004;36:817–823. MEDLINE |
CrossRef
Weir et al., 2003. 94.Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst. 2003;95:1276–1299. Weis, 1998. 95.Weis K. Importins and exportins: how to get in and out of the nucleus. Trends Biochem. Sci. 1998;23:185–189. MEDLINE |
CrossRef
Wiedmann et al., 2003. 96.Wiedmann M, Caca K, Berr F, Schiefke I, Tannapfel A, Wittekind C, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer. 2003;97:2783–2790. Williams and Baum, 2003. 97.Williams DA, Baum C. Medicine. Gene therapy—new challenges ahead. Science. 2003;302:400–401.
CrossRef
Wilson et al., 2002. 98.Wilson KC, Cruikshank WW, Center DM, Zhang Y. Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. Biochemistry. 2002;41:14306–14312. Xiao et al., 1996. 99.Xiao CY, Hubner S, Elliot RM, Caon A, Jans DA. A consensus cAMP-dependent protein kinase (PK-A) site in place of the CcN motif casein kinase II site simian virus 40 large T-antigen confers PK-A-mediated regulation of nuclear import. J. Biol. Chem. 1996;271:6451–6457. MEDLINE |
CrossRef
Xiao et al., 1997. 100.Xiao CY, Hubner S, Jans DA. SV40 large tumor antigen nuclear import is regulated by the double-stranded DNA-dependent protein kinase site (serine 120) flanking the nuclear localization sequence. J. Biol. Chem. 1997;272:22191–22198. MEDLINE |
CrossRef
Xiao et al., 1998. 101.Xiao CY, Jans P, Jans DA. Negative charge at the protein kinase CK2 site enhances recognition of the SV40 large T-antigen NLS by importin: effect of conformation. FEBS Lett. 1998;440:297–301. Abstract | Full Text |
Full-Text PDF (217 KB)
|
CrossRef
Young et al., 2006. 102.Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J. Pathol. 2006;208:299–318. MEDLINE |
CrossRef
Zhang et al., 2004. 103.Zhang YH, Kooistra K, Pietersen A, Rohn JL, Noteborn MH. Activation of the tumor-specific death effector apoptin and its kinase by an N-terminal determinant of simian virus 40 large T antigen. J. Virol. 2004;78:9965–9976.
CrossRef
Zhuang et al., 1995. 104.Zhuang SM, Landegent JE, Verschueren CA, Falkenburg JH, van Ormondt H, van der Eb AJ, et al. Apoptin, a protein encoded by chicken anemia virus, induces cell death in various human hematologic malignant cells in vitro. Leukemia. 1995;9(Suppl. 1):S118–S120. a Nuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Australia b ARC Centre of Excellence for Biotechnology and Development, Australia  Corresponding author at: Nuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Wellington Road, Clayton Vic. 3168, Australia.
PII: S1368-7646(06)00020-3 doi:10.1016/j.drup.2006.02.003 © 2006 Elsevier Ltd. All rights reserved. | |
|
FULL TEXT
